趋化因子配体18在肝细胞癌中的表达及其对临床病理特征和预后的影响

Expression of chemokine ligand-18 in hepatocellular carcinoma and its influence on the clinicopathological features and prognosis

目的探讨趋化因子配体18(CCL18)在肝细胞癌中的表达及其对临床病理特征和预后的影响。方法选取40例肝细胞癌患者作为研究对象,选取肝细胞癌旁肝组织标本和因良性肝占位行手术切除的正常肝组织标本各40份作为对照。应用免疫组织化学法检测CCL18在肝细胞癌及正常肝组织中的表达,比较CCL18在各组中的阳性表达率。分析肝细胞癌组织中CCL18的阳性表达与临床病理特征的关系,应用Kaplan-Meier法分析CCL18表达对肝细胞癌预后的影响。结果 CCL18在肝细胞癌组织中的阳性表达率为72.5%(29/40),在癌旁肝组织中的阳性表达率为7.5%(3/40),在正常肝组织中的阳性表达率为5.0%(2/40),肝癌组织中CCL18的阳性表达率显著高于正常肝组织和癌旁肝组织(χ2=9.251,P<0.05)。随着病理分化程度的降低CCL18的阳性表达率显著增高,有病灶转移的患者中CCL18阳性表达率显著高于无病灶转移的患者。CCL18阳性的肝细胞癌患者的无进展生存期和总生存期显著短于CCL18阴性的肝细胞癌患者。结论 CCL18在肝细胞癌组织中的阳性表达显著增强,且影响患者的预后,CCL18阴性表达的肝细胞癌患者具有更长的生存期。

Objective To investigate the expression and clinical significance of chemokine ligand-18(CCL18)in hepatocellular carcinoma(HCC).Methods Forty patients with HCC in our hospital were enrolled.Normal liver tissues adjacent to HCC,as well as normal liver tissues resected from benign liver lesions,were selected as controls.Hepatic expression of CCL18 were detected using immunohistochemistry,and its relationship with clinicopathological features was analyzed.Effect of CCL18 on prognosis of HCC was analyzed using Kaplan-Meier method.Results The positive expression rates of CCL18 in HCC tissues,paracancerous tissues and normal liver tissues were 72.5%,7.5%and 5.0%,respectively.CCL18 expression significantly increased in patients with poor pathological differentiation and metastasis.The progressionfree survival and overall survival in CCL18 negative expression group were significantly higher than those in the positive expression group(P<0.05).Conclusion The positive expression rate of CCL18 was significantly higher in HCC than that in control cases,and closely related to the prognosis.HCC patients with negative hepatic CCL18 might have a longer survival.